ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
FDA approves Celgene’s R2 for two types of indolent lymphoma
May 30, 2019Celgene has announced that the US Food and Drug Administration (FDA) has approved Revlimid (lenalidomide) in combination with rituximab (R2) for patients with ... -
Rituximab found to extend progression-free survival in indolent lymphoma
March 27, 2019New trial results have been published showing that a combination of Celgene's Revlimid and Roche's rituximab (R2) significantly extended progression-free survival in patients with relapsed or refractory indolent lymphoma, compared to rituximab with placeb
Pharma Sources Insight January 2025
